Preexposure Prophylaxis with Albumin-Conjugated C34 Peptide HIV-1 Fusion Inhibitor in SCID-hu Thy/Liv Mice | Zendy

Cheryl A. Stoddart | Zendy; Geneviève Nault | Zendy; Sofiya A. Galkina | Zendy; Nathalie Bousquet-Gag | Zendy; Dominique Bridon | Zendy; Omar Quraishi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Preexposure Prophylaxis with Albumin-Conjugated C34 Peptide HIV-1 Fusion Inhibitor in SCID-hu Thy/Liv Mice

Author(s) -

Cheryl A. Stoddart,

Geneviève Nault,

Sofiya A. Galkina,

Nathalie Bousquet-Gag,

Dominique Bridon,

Omar Quraishi

Publication year - 2012

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.05015-11

Subject(s) - gp41 , in vivo , peptide , heptad repeat , albumin , pharmacology , human immunodeficiency virus (hiv) , virology , rna , human serum albumin , chemistry , medicine , microbiology and biotechnology , biology , immunology , biochemistry , antigen , peptide sequence , gene , epitope

PC-1505 is a C34 peptide derived from the heptad repeat 2 region of HIV-1 gp41 conjugated to human serum albumin for sustained in vivo activity. One single preexposure dose of PC-1505 reduced viral RNA in HIV-1-infected SCID-hu Thy/Liv mice by 3.3 log₁₀ and protected T cells from virus-mediated depletion. In contrast, a single preexposure dose of Truvada reduced viral RNA by only 0.8 log₁₀ and was substantially less effective in preventing T cell depletion.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research